Securities Code: 300238 Securities Abbreviation: Guanhai Biotechnology Announcement No.: 2026-038
Guanhai Biotechnology Co., Ltd.
Announcement of Resolutions of the Second Meeting of the Seventh Board of Directors
The company and all members of the Board of Directors guarantee that the information disclosed is true, accurate, and complete, and contains no false records, misleading statements, or major omissions.
I. Convening of the Board Meeting
-
The Second Meeting of the Seventh Board of Directors of Guanhai Biotechnology Co., Ltd. (hereinafter referred to as the "Company") was convened. The meeting notice was delivered to all directors on August 10, 2026, via personal delivery, mail, and other methods.
-
The meeting was held on August 11, 2026, at 14:00 in the company's conference room, combining on-site and teleconference methods.
-
A total of 5 directors were eligible to attend, and 5 directors actually attended. Among them, independent directors Mr. Deng Chao and Ms. Yang Biyun attended via teleconference.
-
The meeting was convened and presided over by Mr. Zhang Yongming, Chairman of the Company. Some senior management personnel of the company were present at the meeting.
-
The convening and holding of this meeting comply with the relevant provisions of the "Company Law," "Articles of Association," and "Rules of Procedure for Board Meetings."
II. Deliberation of Board Meeting Matters
The meeting adopted a vote by name. After careful deliberation and voting by the attending directors, the following resolutions were formed:
(I) Deliberation and Approval of the "Proposal on the Bidding Results of the Company's 2026 Targeted Private Placement of Shares"
In accordance with the relevant provisions of the "Securities Law," "Administrative Measures for the Registration and Issuance of Securities by Listed Companies," and the "Implementation Rules for the Issuance and Underwriting Business of Securities by Shenzhen Stock Exchange Listed Companies," and authorized by the Company's 2025 Annual General Meeting, the Company and the lead underwriter sent the "Guanhai Biotechnology Co., Ltd. 2026 Targeted Private Placement Share Subscription Invitation Letter" (hereinafter referred to as the "Subscription Invitation Letter") and its attachments to eligible investors from August 3 to August 5, 2026. Based on the subscription quotations from investors on August 6, 2026, and in accordance with the principles for determining the issuance objects, issuance price, and allocated shares in the "Subscription Invitation Letter," the final bidding results for the Company's targeted private placement of shares (hereinafter referred to as the "Current Issuance") are as follows:
| No. | Name/Name of Investor | Number of Shares Subscribed | Amount of Shares Subscribed (RMB) |
|---|---|---|---|
| 1 | Yuecai (Zhongshan) Bio-pharmaceutical Investment Partnership (Limited Partnership) | 5,870,841 | 59,999,995.02 |
| 2 | Yang Yin | 1,712,330 | 17,500,012.60 |
| 3 | Nord Fund Management Co., Ltd. | 978,473 | 9,999,994.06 |
| 4 | Caitong Fund Management Co., Ltd. | 978,473 | 9,999,994.06 |
| Total | 9,540,117 | 97,499,995.74 |
The final issuance amount is subject to the approval by the Shenzhen Stock Exchange (hereinafter referred to as the "SZSE") and the registration and issuance approval by the China Securities Regulatory Commission (hereinafter referred to as the "CSRC"). If the issuance amount is adjusted due to changes in regulatory policies, issuance review, and registration document requirements, the total number of shares issued and the total amount of funds raised will be adjusted accordingly. The Board of Directors will handle this directly as required by the CSRC, SZSE, and other regulatory authorities, without further board deliberation.